Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Doripenem for Nosocomial and Ventilator-Associated Pneumonia
2007-005633-10Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doripenem in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical response at test-of-cure (TOC) and Pathogen burden over time. Started Dec 2007; status: completed.
02
Drugs
doripenem
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2007-005633-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005633-10.